Answers are grounded in this paper and cite their sources.
Summary: BLU-667 is a next-generation RET inhibitor that maximizes on-target and minimizes off-target effects. It is an exemplar of genotype-driven drug development followed by multi-histology basket trial validation that is becoming a paradigm for precision oncology. Cancer Discov; 8(7); 797–9.
No takes yet. Share an insight, caveat, or question.
Iams et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: